Godrej Agrovet Ltd Q2 FY26 Earnings Analysis

- Overall top-line growth for FY '26 is expected in the early teens, with a 16%-18% growth guidance maintained. (Page 5) - Crop protection standalone revenue growth is uncertain currently due to poor Hitweed product performance; better clarity expected after 3-4 weeks. (Page 15) - Astec LifeSciences aims for EBITDA break-even in FY '26, targeting Rs. 500 crore turnover with CDMO and new products growing over 30% annually beyond FY '26. (Pages 6, 13-14) - CDMO business revenue target is over Rs. 300 crore in FY '26, making up 65% of total sales. (Page 13) - Ashitaka herbicide has a theoretical market potential of about Rs. 200 crore over 3-4 years, with corn acreage growth supporting this. (Page 6) - Oil palm Fresh Fruit Bunch (FFB) arrivals are expected to grow 15%-18% in FY '26; oil extraction ratio (OER) expected better than FY '25's 19%. (Page 15) - Dairy segment aims to increase value-added product share to 50% in two years, improving EBITDA margins. (Page 12)

- Top-line growth for Godrej Agrovet Limited (GAVL) expected in early teens for FY '26 with profit growth maintained as per Q1 FY '26. - Astec LifeSciences aims for EBITDA break-even in FY '26, targeting Rs. 500 crores turnover; CDMO business expected to grow over 30% annually beyond FY '26. - Oil extraction ratio (OER) in palm oil segment expected to improve 15%-18% in FY '26, supporting profitability. - Dairy segment EBITDA margins targeted at 6%-7% for FY '26 despite increased ad spends, with value-added product share expected to rise. - Crop protection margins under pressure but expected to stabilize; new product launches (e.g., Ashitaka) anticipated to drive growth. - Overall consolidated profit growth was 25% in Q1 FY '26 over last year, indicating strong earnings momentum.

- Significant investments made recently include close to Rs. 1,250 crores in the last six months for buying out partners in Godrej Foods and Creamline Dairy to achieve 100% ownership, enabling cleaner portfolio decisions (Page 12). - Refitting of old plants for commercializing new CDMO products is planned; current new projects will be based on existing old plants with multipurpose capabilities allowing adjustments and refitting as needed (Page 13). - Mention of CapEx in last 2-3 years involving new plants to support CDMO products signifies ongoing capacity-building investments (Page 13). - No explicit future capex figures or timelines disclosed; growth in CDMO business and new product launches imply continued strategic investments.

- The recent rights issue proceeds for Astec LifeSciences are being utilized primarily for debt repayment, as mentioned by S. Varadaraj. - There is no explicit mention of any new or planned fundraising through debt or equity in the current transcript. - The company appears focused on strategic clean-up of ownership, such as fully acquiring Godrej Foods and Creamline Dairy, funded by past investments (~Rs. 1,250 crores), rather than fresh fundraising. - Any future capital requirements or fundraising plans beyond this are not detailed in this call. - Management emphasizes growth and margin improvement funded through operational improvements and internal resources rather than new external fundraising at present.

The transcript provided does not contain specific details on the current or expected order book or pending orders for Godrej Agrovet Limited. The discussion primarily focuses on: - Financial performance and outlook for FY '26 - FFB arrivals and oil extraction ratios in FY '25 and expectations for FY '26 - Crop protection business performance and outlook - Value-added product focus in various segments - CDMO business traction and outlook - No explicit mention of order book status or pending orders in the transcript. If you need detailed order book information, it might be available in other company filings or investor presentations not included here.